What Are the Stages of Depression?

Depression does not follow a single, fixed sequence of stages the way cancer does, but researchers have developed clinical staging models that map where a person sits along the illness’s continuum, from early vulnerability through acute episodes and into chronic or recurrent forms. These models typically distinguish a prodromal phase of subtle symptoms, one or more acute episodes of varying severity, a period of remission or recovery, and in some cases a progression into treatment-resistant or chronic depression. Understanding how depression tends to unfold over time can change the way you think about warning signs, treatment decisions, and long-term outlook.

Why Researchers Talk About “Stages” at All

In oncology, staging is standard practice: you identify how far a disease has progressed and tailor treatment accordingly. Psychiatry has been slower to adopt this approach, but a growing body of work argues that depression is better understood as a condition that moves through identifiable phases rather than as a single state that is either present or absent. One prominent framework proposes eight consecutive stages (labeled 0 through 4, with some subdivisions) defined by symptom severity, episode duration, and the number of prior episodes a person has experienced.¹ The clinical staging idea is not universally adopted, but it serves a practical purpose: matching the intensity of treatment to where someone actually is in the illness course, rather than treating every presentation the same way.²

The appeal of staging is that it acknowledges what clinicians see every day: a first mild episode in a 22-year-old with no prior history is a fundamentally different clinical situation from a fourth severe episode in a 50-year-old who has never fully recovered between bouts. Treating those two scenarios identically makes about as much sense as giving the same cancer treatment to a Stage I and Stage IV patient. The staging concept pushes clinicians to think longitudinally, tracking how the illness evolves rather than just whether it is currently present.

The Prodromal Phase

Before a full depressive episode arrives, many people experience a buildup of milder symptoms that researchers call the prodrome. These subthreshold signs can linger for weeks or months and often go unrecognized because they do not meet the formal criteria for a depressive episode. A person might notice persistent low energy, mild sleep disturbances, vague irritability, or difficulty concentrating without connecting those feelings to what is coming next.³

Longitudinal research has found that people who go on to develop a depressive episode show significantly more depressive symptoms in the run-up period compared with those who do not develop an episode. Seven specific symptoms were particularly likely to appear before the onset of a full episode.⁴ The prodrome matters because it represents a window of opportunity. If you or someone close to you can recognize those early shifts in mood, energy, and engagement, it opens the door to intervention before the full weight of an episode lands.

One biological pathway that helps explain this gradual buildup involves the immune system. Social stress and adversity can ramp up inflammatory signaling in the body, and the resulting proinflammatory molecules can trigger behavioral changes strikingly similar to depressive symptoms: sadness, loss of interest, fatigue, slowed movement, and social withdrawal.⁵ This does not mean every prodrome is inflammation-driven, but it illustrates how the body’s stress response can set the stage for a depressive episode to take hold gradually rather than appearing overnight.

The Acute Episode and Its Severity Spectrum

Once someone crosses the threshold into a full depressive episode, the experience is not uniform. Diagnostic criteria treat depression as a single diagnosis, but severity varies enormously from person to person and episode to episode. Clinicians generally distinguish mild, moderate, and severe presentations, and the symptoms that matter most shift as severity increases. Research has found that persistent depressed mood is the symptom that best separates people without depression from those with mild depression, while loss of interest or pleasure (anhedonia) is what best separates severe depression from moderate.⁶

When researchers have examined which individual symptoms track most closely with overall severity, suicidal thoughts show the strongest correlation with how severely ill a clinician rates the patient. All nine standard diagnostic criteria contribute meaningfully to severity, but physical symptoms like appetite and weight changes are the weakest predictors.⁷ What this means in practical terms is that the character of a depressive episode changes as it deepens. A mild episode might feel like persistent low mood and fatigue. A severe episode reorganizes a person’s entire inner life, pulling interest, pleasure, sleep, appetite, concentration, and self-worth into its gravity.

Psychotic Depression as the Far End of Severity

At the extreme end of the severity spectrum, some people develop what clinicians call psychotic depression: a depressive episode accompanied by hallucinations, delusions, or both. This is not a separate illness but rather a severe variant of major depression, and it carries a meaningfully worse course. Patients with psychotic depression show higher levels of overall psychopathology and more severe self-reported depression and anxiety compared with those whose episodes are equally severe on mood measures alone but lack psychotic features.⁸

Inpatient studies have found that people with psychotic depression have worse clinical and functional parameters at both admission and discharge, even when their raw depression scores are similar to those of non-psychotic patients. This reinforces the view that psychotic features indicate a more severe form of the illness beyond what mood symptom ratings alone capture.⁹ The long-term picture is also harder: people with psychotic depression have substantially higher rates of relapse and recurrence and shorter times between episodes, even after accounting for the fact that they tend to be more severely depressed at baseline.¹⁰

If you or someone you know has experienced depression with any form of hallucination or fixed false belief (for instance, an unshakeable conviction of having committed a terrible crime, or hearing a voice that confirms worthlessness), that is a signal to seek aggressive treatment. Psychotic depression responds poorly to antidepressants alone and typically requires a combination approach.

Remission, Recovery, and the Gray Zone Between Them

When a depressive episode begins to lift, people often assume they are “better.” But the clinical picture is more layered than that. Researchers distinguish several post-episode states, and the differences carry real implications for treatment decisions. Remission means the symptoms have dropped below a clinically meaningful level, but it is a relatively brief and fragile state. Recovery means remission has held long enough that the episode is considered truly over. Relapse is a return of symptoms during the remission window, suggesting the original episode was suppressed rather than resolved. Recurrence is a return of symptoms after full recovery, meaning a brand-new episode has started.¹¹ These terms are frequently confused, even in clinical writing, but the distinction between relapse and recurrence shapes whether a clinician recommends continuing current treatment or starting a new one.¹²

The gray zone between these states is where many people live for extended stretches. Residual symptoms are extremely common among people classified as being in remission, and they are not trivial: lingering fatigue, mild concentration problems, or low-grade sleep disruption can undermine functioning and relationships long after the formal episode has passed.¹³ More critically, those residual symptoms are one of the strongest predictors of the next episode. A large meta-synthesis found that post-treatment residual symptoms, childhood maltreatment, and a history of recurrence were the most robust indicators of future relapse, and each could be used to decide who benefits most from ongoing preventive treatment.¹⁴

Why Depression Keeps Coming Back

For a long time, the dominant idea was “kindling”: the notion that each depressive episode sensitizes the brain, making the next episode easier to trigger and the gaps between episodes shorter over time. This is an intuitive model, and it influenced decades of clinical thinking. But the evidence for true cycle acceleration is weaker than many people assume. A careful reanalysis found that when you correct for a statistical artifact (the tendency for highly recurrent individuals to show up in studies precisely because their episodes are frequent), the appearance of shrinking gaps between episodes largely disappears. Instead, people who have short intervals between episodes tend to have had short intervals from the very beginning.¹⁵

That does not mean recurrence is random. It means the vulnerability to frequent episodes is probably built in early (through genetics, developmental adversity, or both) rather than progressively worsened by each episode. One tangible sign that repeated depression leaves a mark, however, is structural: people with a history of major depression have smaller hippocampal volumes, and the degree of shrinkage correlates with the total duration of depressive illness.¹⁶ Whether that shrinkage is a cause or a consequence of depression remains an open question, but it underscores that depression is not purely a “mental” experience — it involves measurable changes in brain structure over time.

Chronic Depression and Treatment Resistance

Some people do not cycle through discrete episodes. Instead, their depression becomes a persistent low-grade companion, sometimes punctuated by deeper dips. When researchers have looked at what drives chronic depression, the strongest factor is developmental: people with histories of childhood adversity are disproportionately represented among those whose depression becomes entrenched. Ongoing environmental stress and a heightened stress reactivity also contribute, but the determinants of chronic depression do not differ fundamentally from those of acute depression — they are the same factors, amplified.¹⁷ Other risk factors for chronic courses include younger age at onset, longer initial episode duration, family history of mood disorders, co-occurring anxiety or personality disorders, and low social support.¹⁸

When standard antidepressants fail, clinicians turn to staging models designed specifically for treatment resistance. At least five such models exist, the best-known being the Maudsley Staging Model, which scores treatment resistance along three dimensions: how many adequate medication trials have failed, how severe current symptoms are, and how long the episode has lasted.¹⁹²⁰ For people at the higher stages of treatment resistance, options include electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and intravenous ketamine. A recent network meta-analysis comparing these three approaches for Stage 2 or higher treatment-resistant depression found no significant difference in response or remission rates among them, though the confidence of the evidence remains low, especially for ketamine versus ECT.²¹ The practical takeaway is that if standard medications have not worked, other options exist and appear roughly comparable in effectiveness. Identifying which patients respond best to which intervention remains an active research challenge.²²

Perinatal Depression Has Its Own Trajectories

Depression during pregnancy and the postpartum period does not follow a single arc. Longitudinal studies tracking women from early pregnancy through the first year after birth have identified distinct trajectories. In one large study, roughly 90% of women maintained low depressive symptoms throughout, about 5% had elevated symptoms mainly during pregnancy, and another 5% developed symptoms mainly after delivery. More than half of those who did experience depressive symptoms had their first signs during early pregnancy, not after the baby was born.²³

Among women who develop postpartum depression, roughly half show improvement within six months, while the other half do not recover in that window. A small percentage of initially healthy women develop major depression within the first postpartum year, and the risk climbs considerably for those who had early subthreshold symptoms. Persistent postpartum depression is characterized by an accumulation of risk factors including prior depression, childhood maltreatment, low social support, and premenstrual syndrome, while the recovering cases tend to be driven more by hormonal sensitivity.²⁴

The longer-term outlook is sobering. Within five years of a postpartum episode, more than 40% of women developed a new episode of depression, compared with under 4% of women without a postpartum history. Over a third of those who went on to have more children experienced postpartum depression again.²⁵ These numbers reinforce that postpartum depression is not a self-contained event but often the opening chapter of a recurrent mood disorder.

How Culture Shapes What Depression Looks Like

One complication with any staging framework is that depression does not look the same across cultures. In many communities, psychological distress expresses itself primarily through physical complaints — headaches, chest pain, dizziness, fatigue — rather than through the sadness and guilt that Western diagnostic criteria emphasize. These somatic symptoms serve as culturally shaped ways of communicating distress, and when clinicians from one cultural background evaluate patients from another, the mismatch can lead to missed diagnoses, unnecessary medical workups, or inappropriate treatment.²⁶ A staging model built on symptom severity and episode counting only works if the symptoms are being identified correctly in the first place. For people from cultural backgrounds where emotional distress is expressed through the body, early prodromal signs may look nothing like what a textbook describes.

Tracking Depression’s Movement With Passive Digital Data

An emerging area of research uses smartphone and wearable sensor data to detect shifts in a person’s depressive state before they or their clinician notice. The idea is straightforward: your phone already knows how much you move, how you sleep, how often you interact socially, and how your daily routines change. Systematic reviews of this “digital phenotyping” approach have found that disrupted sleep, reduced physical movement, and changes in social communication form a reliable set of warning signals. In depression, these behavioral markers can flag an approaching relapse up to four weeks before it is clinically confirmed.²⁷ This technology is still largely in the research phase, and there are real questions about privacy, accuracy, and what to do with a relapse warning once you get one. But for people with highly recurrent depression, the possibility of an early-warning system that works in the background of daily life is genuinely promising. It aligns naturally with the staging concept: the earlier you can identify where someone is headed on the illness continuum, the lighter the intervention needed to change course.

An Evolutionary Angle on Why Depression Unfolds the Way It Does

One reason depression follows a staged, progressive pattern rather than simply switching on and off may be rooted in how the response evolved. A unified evolutionary model proposes that depressive symptoms originally served as an energy-conservation strategy after the perceived loss of something vital — a relationship, group membership, or key personal resource. The withdrawal, fatigue, and reduced motivation that characterize depression may have been adaptive in ancestral environments, prompting a person to disengage from a losing situation and conserve resources.²⁸ In this framework, the prodromal phase corresponds to the early appraisal of loss, the acute episode to full energy-conservation mode, and recovery to a gradual re-engagement once circumstances shift. The model does not excuse the suffering — these ancient responses are maladaptive in modern life, where the “losses” are often symbolic and the withdrawal can spiral into chronic illness. But it offers a lens for understanding why depression has a characteristic shape: a buildup, a peak, and an eventual (though not guaranteed) easing, rather than a random scattering of bad days.

Early biological research is also trying to find molecular signatures that correspond to different phases. A recent study found that people in the early stage of depression showed a distinct pattern of elevated inflammatory markers and growth factors alongside reductions in gray matter in limbic brain regions including the hippocampus, amygdala, and insula.²⁹ This is very preliminary work, but it hints at a future where blood tests and brain imaging could help place a person on the staging continuum, much the way oncologists use biomarkers to stage cancer. For now, staging depression still relies on symptom history and clinical judgment, but the field is clearly moving toward something more objective.